Literature DB >> 18046048

Pharmacokinetics and pharmacodynamics of oral testosterone enanthate plus dutasteride for 4 weeks in normal men: implications for male hormonal contraception.

John K Amory1, Thomas F Kalhorn, Stephanie T Page.   

Abstract

Oral administration of testosterone enanthate (TE) and dutasteride increases serum testosterone and might be useful for male hormonal contraception. To ascertain the contraceptive potential of oral TE and dutasteride by determining the degree of gonadotropin suppression mediated by 4 weeks of oral TE plus dutasteride, 20 healthy young men were randomly assigned to 4 weeks of either 400 mg oral TE twice daily or 800 mg oral TE once daily in a double-blinded, controlled fashion at a single site. All men received 0.5 mg dutasteride daily. Blood for measurement of serum luteinizing hormone (LH), follicle-stimulating hormone (FSH), testosterone, dihydrotesterone (DHT), and estradiol was obtained prior to treatment, weekly during treatment, and 1, 2, 4, 8, 12, 13, 14, 16, 20, and 24 hours after the morning dose on the last day of treatment. FSH was significantly suppressed throughout treatment with 800 mg TE once daily and after 4 weeks of treatment with 400 mg TE twice daily. LH was significantly suppressed after 2 weeks of treatment with 800 mg TE, but not with 400 mg TE. Serum DHT was suppressed and serum estradiol increased during treatment in both groups. High-density lipoprotein cholesterol was suppresed during treatment, but liver function tests, hematocrit, creatinine, mood, and sexual function were unaffected. The administration of 800 mg oral TE daily combined with dutasteride for 28 days significantly suppresses gonadotropins without untoward side effects and might have utility as part of a male hormonal contraceptive regimen.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18046048      PMCID: PMC2664381          DOI: 10.2164/jandrol.107.004226

Source DB:  PubMed          Journal:  J Androl        ISSN: 0196-3635


  23 in total

1.  Potential impact of hormonal male contraception: cross-cultural implications for development of novel preparations.

Authors:  C W Martin; R A Anderson; L Cheng; P C Ho; Z van der Spuy; K B Smith; A F Glasier; D Everington; D T Baird
Journal:  Hum Reprod       Date:  2000-03       Impact factor: 6.918

2.  The importance of dual 5alpha-reductase inhibition in the treatment of male pattern hair loss: results of a randomized placebo-controlled study of dutasteride versus finasteride.

Authors:  Elise A Olsen; Maria Hordinsky; David Whiting; Dow Stough; Stuart Hobbs; Melissa L Ellis; Timothy Wilson; Roger S Rittmaster
Journal:  J Am Acad Dermatol       Date:  2006-12       Impact factor: 11.527

3.  Testosterone gel combined with depomedroxyprogesterone acetate is an effective male hormonal contraceptive regimen and is not enhanced by the addition of a GnRH antagonist.

Authors:  Stephanie T Page; John K Amory; Bradley D Anawalt; Michael S Irwig; Andrew T Brockenbrough; Alvin M Matsumoto; William J Bremner
Journal:  J Clin Endocrinol Metab       Date:  2006-08-29       Impact factor: 5.958

4.  Aromatase inhibition in the human male reveals a hypothalamic site of estrogen feedback.

Authors:  F J Hayes; S B Seminara; S Decruz; P A Boepple; W F Crowley
Journal:  J Clin Endocrinol Metab       Date:  2000-09       Impact factor: 5.958

5.  Differential regulation of gonadotropin secretion by testosterone in the human male: absence of a negative feedback effect of testosterone on follicle-stimulating hormone secretion.

Authors:  F J Hayes; S DeCruz; S B Seminara; P A Boepple; W F Crowley
Journal:  J Clin Endocrinol Metab       Date:  2001-01       Impact factor: 5.958

6.  Will Australian men use male hormonal contraception? A survey of a postpartum population.

Authors:  Gareth C Weston; Michelle L Schlipalius; Meabh Ni Bhuinneain; Beverley J Vollenhoven
Journal:  Med J Aust       Date:  2002-03-04       Impact factor: 7.738

7.  The effect of 5alpha-reductase inhibition with dutasteride and finasteride on semen parameters and serum hormones in healthy men.

Authors:  John K Amory; Christina Wang; Ronald S Swerdloff; Bradley D Anawalt; Alvin M Matsumoto; William J Bremner; Susan E Walker; Lynda J Haberer; Richard V Clark
Journal:  J Clin Endocrinol Metab       Date:  2007-02-13       Impact factor: 5.958

8.  Analysis of testosterone and dihydrotestosterone from biological fluids as the oxime derivatives using high-performance liquid chromatography/tandem mass spectrometry.

Authors:  Thomas F Kalhorn; Stephanie T Page; William N Howald; Elahe A Mostaghel; Peter S Nelson
Journal:  Rapid Commun Mass Spectrom       Date:  2007       Impact factor: 2.419

9.  The influence of finasteride on the development of prostate cancer.

Authors:  Ian M Thompson; Phyllis J Goodman; Catherine M Tangen; M Scott Lucia; Gary J Miller; Leslie G Ford; Michael M Lieber; R Duane Cespedes; James N Atkins; Scott M Lippman; Susie M Carlin; Anne Ryan; Connie M Szczepanek; John J Crowley; Charles A Coltman
Journal:  N Engl J Med       Date:  2003-06-24       Impact factor: 91.245

Review 10.  Androgenetic alopecia.

Authors:  Nina Otberg; Andreas M Finner; Jerry Shapiro
Journal:  Endocrinol Metab Clin North Am       Date:  2007-06       Impact factor: 4.741

View more
  3 in total

1.  Testosterone, HDL and cardiovascular risk in men: the jury is still out.

Authors:  Katya B Rubinow; Stephanie T Page
Journal:  Clin Lipidol       Date:  2012-08-01

2.  Steady-state pharmacokinetics of oral testosterone undecanoate with concomitant inhibition of 5α-reductase by finasteride.

Authors:  M Y Roth; R E Dudley; L Hull; A Leung; P Christenson; C Wang; R Swerdloff; J K Amory
Journal:  Int J Androl       Date:  2010-10-24

3.  Estrogens and development of the rete testis, efferent ductules, epididymis and vas deferens.

Authors:  Rex A Hess; Richard M Sharpe; Barry T Hinton
Journal:  Differentiation       Date:  2020-12-13       Impact factor: 3.880

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.